Boundless Bio (BOLD) Liabilities and Shareholders Equity (2023 - 2026)

Boundless Bio (BOLD) has reported Liabilities and Shareholders Equity for 4 consecutive years, with $141.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 26.29% year-over-year to $141.0 million; the TTM figure through Mar 2026 stood at $646.2 million (down 15.08% YoY), while the FY2025 annual figure was $157.1 million, down 23.91% from the prior year.
• Liabilities and Shareholders Equity fell to $141.0 million in Q1 2026 per BOLD's latest filing, from $157.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $206.4 million in Q4 2024 and bottomed at $117.1 million in Q1 2024.
• Historically, Liabilities and Shareholders Equity has averaged $165.4 million across 4 years, with a median of $171.9 million in 2024.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity surged 63.35% — and 2026, when it fell 26.29%.
• Boundless Bio's Liabilities and Shareholders Equity stood at $129.9 million in 2023, then jumped by 58.91% to $206.4 million in 2024, then declined by 23.91% to $157.1 million in 2025, then dropped by 10.24% to $141.0 million in 2026.
• Business Quant data shows BOLD's Liabilities and Shareholders Equity at $141.0 million in Q1 2026, $157.1 million in Q4 2025, and $168.7 million in Q3 2025.